

Non-Executive Director Resignation

28 October 2021

4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”), a medical technology company focused on commercialising its FDA-cleared and TGA-approved respiratory imaging platform, hereby advises that Ms Lusia Guthrie has resigned as Non-Executive Director of the Company, effective as of the conclusion of 4DMedical’s 2021 Annual General Meeting, held earlier today. Ms Guthrie continues to be engaged with the 4DMedical group of companies through her important role as Non-Executive Director and Chair of the Company’s wholly owned subsidiary, Australian Lung Health Initiative Pty Ltd, which is seeking to deliver the world’s first dedicated lung scanner integrated with XV Technology™. 4DMedical thanks Ms Guthrie sincerely for her valued contributions to the Company since 2017.

Ms Guthrie’s Appendix 3Z is attached.

–ENDS–

Authorised by Charlene Stahr, Company Secretary.

Contacts

Corporate

Charlene Stahr
Company Secretary
companysecretary@4dmedical.com

Investor

Simon Hinsley
+ 61 401 809 653
shinsley@4dmedical.com

Media

Matthew Wright
+ 61 451 896 420
matt@nwrcommunications.com.au

About 4DMedical

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. Through its technology, 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Lusia Guthrie
Date of last notice	12 April 2021
Date that director ceased to be director	28 October 2021

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 207,409 fully paid ordinary shares held jointly with Hugh Guthrie as trustees for the Podlaska Superannuation Fund

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of securities
Note: Provide details of the circumstances giving rise to the relevant interest	N/A

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.